News | September 05, 2014

Participants of Cardiac Clinic Trials Do Not Represent Real World Patients, Study Finds

Study calls for broader enrollment in clinical trials to improve generalizability of studies in patients with heart disease

September 5, 2014 — A new analysis of clinical trial participation in the largest ongoing observational study of U.S. heart attack patients has found participants are not representative of the larger patient base, according to a study led by Women’s College Hospital cardiologist Jay Udell. The study authors call into question the general applicability of the findings to the wider population, and suggest the use of broader enrollment criteria and existing patient registries to increase trial participation.

“We know that clinical trials can be tremendously expensive and a huge burden on our healthcare system,” said Udell. “Our study shows participants often reflect a small portion of the typical patients we see in offices and hospitals, and we are missing a large number of potentially eligible patients who are right at our fingertips.”

The study, published in the Journal of the American Medical Association, reviewed data collected from the American College of Cardiology’s National Cardiovascular Data Registry of heart attack patients treated at 466 hospitals across the United States from July 1, 2008 to March 31, 2011. The researchers found:

Less than three per cent of patients (4,008 patients) were enrolled in the clinical trial during hospitalization.

An estimated 66 percent were eligible to participate but did not.

Trial participants were:

  • Younger
  • More frequently male
  • Had less previous heart disease and shorter hospital stays
  • Had faster access to diagnostic testing, and
  • More frequently received recommended medical therapy within the first 24 hours of hospitalization, prescribed exercise and diet counseling, and referral to a cardiac rehab centre.


Trial Participants Had the Best Health Outcomes

Those who were eligible to participate in the trial but did not had a nearly two times greater risk of dying compared to trial participants. While the findings are significant, the authors caution that trial participants are likely chosen because of anticipated health and compliance; added links between clinical trial participation and optimal health require further research. However, the authors emphasize the results provide valuable information that may help scientists find ways to improve clinical trial enrolment.

“Cardiac trial participants represent a low-risk population with more favourable care and outcomes compared with the typical heart attack patients we see in routine practice,” noted Udell. “What this tells us loud and clear is that we have an opportunity to do better — there is a huge cadre of patients that we should be studying by better leveraging data from our national and provincial patient registries while continuing to maintain our highest standard of data privacy and safety.”

Clinical trials, a gold standard for testing new therapies and treatments for disease, are costly and often have poor enrollment.

“Rather than reinventing the wheel and continuing to perform each costly clinical trial starting from scratch, we should be using these registries to boost participation in clinical trials, so that we can minimize study co-ordination, data monitoring and clinical followup — all of which pose significant financial barriers to launching a clinical trial,” said Udell. “With minimal investment, we can transform our current electronic health records and healthcare service databases to serve this dual purpose, and provide an infrastructure with economies of scale to support multiple clinical trials at a fraction of the cost of one traditional study.”

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init